Summary
Summary Abouttwo-thirds of longAbouttwo-thirds of longterm users of benzodiazepines in the term users of benzodiazepines in the population are able to discontinue this population are able to discontinue this drug with the aid of supervised drug with the aid of supervised programmes for tapering off.Little is programmes for tapering off.Little is known aboutthe long-term outcome of known aboutthe long-term outcome of such programmes, and they have never such programmes, and they have never been compared with usual care. After a been compared with usual care. After a 15-month follow-up of a randomised 15-month follow-up of a randomised controlled trial comparing such a procontrolled trial comparing such a programme with and without psychotherapy gramme with and without psychotherapy with usual care, we found significantly with usual care, we found significantly higher longitudinal abstinence rates in higher longitudinal abstinence rates in long-term benzodiazepine users who long-term benzodiazepine users who received a benzodiazepine tapering-off received a benzodiazepine tapering-off programme without psychotherapy (25 programme without psychotherapy (25 out of 69, 36%) compared with those who out of 69, 36%) compared with those who received usual care (5 out of 33,15%; received usual care (5 out of 33,15%; P P¼0.03). 0.03).
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Almost two-thirds of long-term benzodiaAlmost two-thirds of long-term benzodiazepine users who take part in benzodiazezepine users who take part in benzodiazepine discontinuation programmes are able pine discontinuation programmes are able to achieve complete abstinence in the short to achieve complete abstinence in the short term (Oude Voshaar term (Oude Voshaar et al et al, 2006) . The long-, 2006) . The longterm outcome studies that have been pubterm outcome studies that have been published are uncontrolled for the natural lished are uncontrolled for the natural course of benzodiazepine usage, and report course of benzodiazepine usage, and report abstinence rates ranging from 16 to 82% abstinence rates ranging from 16 to 82% (Ashton, 1987; Golombok (Ashton, 1987; Golombok et al et al, 1987; , 1987; Rickels Rickels et al et al, 1991; Holton , 1991; Holton et al et al, 1992; , 1992; Couvee Couvée et al et al, 2002) . This paper presents , 2002). This paper presents the results of a 15-month follow-up of the results of a 15-month follow-up of a previously published randomised cona previously published randomised controlled trial (RCT) comparing two benzotrolled trial (RCT) comparing two benzodiazepine tapering-off conditions with a diazepine tapering-off conditions with a control condition consisting of usual care control condition consisting of usual care (Oude Voshaar (Oude Voshaar et al et al, 2003) . , 2003) .
METHOD METHOD
A total of 180 individuals who had been A total of 180 individuals who had been using benzodiazepine for over 3 months using benzodiazepine for over 3 months and were unable to quit their usage of the and were unable to quit their usage of the drug by themselves after receiving a disdrug by themselves after receiving a discontinuation letter from their general continuation letter from their general practitioner were randomly allocated to practitioner were randomly allocated to tapering off with cognitive-behavioural tapering off with cognitive-behavioural group therapy (CBT; group therapy (CBT; n n¼73), tapering off 73), tapering off alone ( alone (n n¼73) or usual care ( 73) or usual care (n n¼34) in 34) in general practice. A detailed description of general practice. A detailed description of the interventions and interview assessments the interventions and interview assessments at baseline and end of treatment is given at baseline and end of treatment is given elsewhere (Oude Voshaar elsewhere (Oude Voshaar et al et al, 2003) . , 2003). The present paper describes: a 15-The present paper describes: a 15-month follow-up; the use of prescription month follow-up; the use of prescription data instead of self-reported benzodiazedata instead of self-reported benzodiazepine usage, with a significantly lower droppine usage, with a significantly lower dropout rate as a consequence; and data on the out rate as a consequence; and data on the prescribing of other drugs during followprescribing of other drugs during followup. All patients gave their informed consent up. All patients gave their informed consent to participate in the follow-up study. Drug to participate in the follow-up study. Drug prescription data were prospectively obprescription data were prospectively obtained from the computerised medical tained from the computerised medical records, and included date of issue, Anatorecords, and included date of issue, Anatomical Therapeutic Chemical classification mical Therapeutic Chemical classification code (ATC code; World Health Organizacode (ATC code; World Health Organization Collaborating Centre for Drugs Statistion Collaborating Centre for Drugs Statistics Methodology, 1996) and name of the tics Methodology, 1996) and name of the drug, number of tablets and dose. Gender, drug, number of tablets and dose. Gender, date of birth and the administration numdate of birth and the administration number of individual participants were exber of individual participants were extracted to link the prescription data with tracted to link the prescription data with the results of the RCT. The primary outthe results of the RCT. The primary outcome measure, benzodiazepine abstinence, come measure, benzodiazepine abstinence, was based on the computerised prescription was based on the computerised prescription data. We analysed the preva data. We analysed the prevalence rates of lence rates of benzodiazepine abstinence and the mean daibenzodiazepine abstinence and the mean daily dosages in diazepam equivalents of all isly dosages in diazepam equivalents of all issued benzodiazepine prescriptions over sued benzodiazepine prescriptions over predefined 3-month periods using predefined 3-month periods using w w 2 2 -tests, -tests, Cox regression analysis and repeated-meaCox regression analysis and repeated-measures analysis of variance (ANOVA). The sures analysis of variance (ANOVA). The secondary outcome measure was the presecondary outcome measure was the prescription of psychotropic drugs other than scription of psychotropic drugs other than benzodiazepines. benzodiazepines.
In addition to the prescription data, we In addition to the prescription data, we also performed a follow-up assessment at also performed a follow-up assessment at 15 months ( 15 months (n n¼143) which was identical 143) which was identical to the baseline ( to the baseline (n n¼180) and outcome 180) and outcome ( (n n¼141) assessments of the RCT. In this 141) assessments of the RCT. In this report, we present the outcome and folreport, we present the outcome and follow-up assessment data for self-reported low-up assessment data for self-reported benzodiazepine usage. benzodiazepine usage.
RESULTS RESULTS
Computerised drug prescription data were Computerised drug prescription data were available for 170 of the 180 participants available for 170 of the 180 participants for the whole study period. However, for the whole study period. However, owing to patient withdrawal from the interowing to patient withdrawal from the interview assessments, data on self-reported view assessments, data on self-reported benzodiazepine usage were available for benzodiazepine usage were available for only 143 participants at the 15-month only 143 participants at the 15-month follow-up. Baseline characteristics did not follow-up. Baseline characteristics did not differ across the three conditions. Patients differ across the three conditions. Patients used benzodiazepines on average for 13.5 used benzodiazepines on average for 13. The longitudinal abstinence rate based The longitudinal abstinence rate based on prescription data for participants who on prescription data for participants who received tapering off plus CBT (20 out of received tapering off plus CBT (20 out of 68, 29%) was not significantly superior to 68, 29%) was not significantly superior to that for those who received usual care that for those who received usual care (5 out of 33, 15%; (5 out of 33, 15%; w w 2 2 ¼2.4, d.f. 2.4, d.f.¼1, 1, P P¼0.12), whereas the opposite was the case 0.12), whereas the opposite was the case for participants who received tapering off for participants who received tapering off alone (25 out of 69, 36%, alone (25 out of 69, 36%, w w 2 2
.f.¼1, 1, P P¼0.03 in favour of tapering off alone; 0.03 in favour of tapering off alone; see data supplement to the online version see data supplement to the online version of this paper). The two active treatment of this paper). The two active treatment groups only differed significantly at 1-3 groups only differed significantly at 1-3 months of follow-up ( months of follow-up (w w 2 2 ¼4.6, d.f. 4.6, d.f.¼1, 1, P P¼0.03), in favour of tapering off alone. 0.03), in favour of tapering off alone. The 'survival curve' to the first benzodiazeThe 'survival curve' to the first benzodiazepine prescription after the intervention pine prescription after the intervention period confirmed these findings (Gehanperiod confirmed these findings (GehanBreslow test: 9.31; d.f. Breslow test: 9.31; d.f.¼2, 2, P P¼0.02). Of the 0.02). Of the participants who restarted benzodiazepine participants who restarted benzodiazepine treatment during follow-up, 90% (113 out treatment during follow-up, 90% (113 out of 126) restarted within the first 9 months. of 126) restarted within the first 9 months.
Self-reported abstinence in the month Self-reported abstinence in the month before the 15-month follow-up assessment before the 15-month follow-up assessment was not significantly different between the was not significantly different between the three groups (tapering off plus CBT, 30 three groups (tapering off plus CBT, 30 out of 58, 52%; tapering off alone, 37 out out of 58, 52%; tapering off alone, 37 out of 59, 63%; usual care, 11 out of 26, of 59, 63%; usual care, 11 out of 26, 42%; 42%; w w 2 2
.f.¼2, 2, P P¼0.19). Kappa for 0.19). Kappa for the agreement of computerised benzodiazethe agreement of computerised benzodiazepine prescription outcome at 13-15 months pine prescription outcome at 13-15 months and self-reported outcome at 15 months and self-reported outcome at 15 months was 0.73 ( was 0.73 (P P5 50.001). Most discrepancies 0.001). Most discrepancies were found in participants who used benzowere found in participants who used benzodiazepines intermittently during follow-up. diazepines intermittently during follow-up.
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A repeated-measures ANOVA showed A repeated-measures ANOVA showed that among participants who did not achieve that among participants who did not achieve continued abstinence, those who received continued abstinence, those who received active treatment used significantly lower active treatment used significantly lower dosages at follow-up compared with those dosages at follow-up compared with those who were assigned usual care ( who were assigned usual care (F F¼6.5, 6.5, d.f. d.f.¼1, 1, P P¼0.01). A significant time 0.01). A significant time6 6group group interaction (active treatment interaction (active treatment v.
v. usual care) usual care) indicated that this difference decreased indicated that this difference decreased during follow-up ( during follow-up (F F¼5.3, d .f.
5.3, d.f.¼1, 1, P P¼0.02). 0.02). The prescription of antidepressants, The prescription of antidepressants, analgesics, antipsychotics and anti-epileptic analgesics, antipsychotics and anti-epileptic drugs remained stable, and patients were not drugs remained stable, and patients were not prescribed hypnotic or anxiolytic drugs other prescribed hypnotic or anxiolytic drugs other than benzodiazepines during follow-up. than benzodiazepines during follow-up.
DISCUSSION DISCUSSION
Although relatively low 15-month longituAlthough relatively low 15-month longitudinal rates for abstinence from benzodiazedinal rates for abstinence from benzodiazepines were found (29% for tapering off plus pines were found (29% for tapering off plus CBT and 36% for tapering off alone), com-CBT and 36% for tapering off alone), comparison with the control group confirmed parison with the control group confirmed the long-term efficacy of tapering off alone. the long-term efficacy of tapering off alone. The high point prevalence of benzodiazepine The high point prevalence of benzodiazepine abstinence in the 3-month follow-up periods abstinence in the 3-month follow-up periods (see data supplement to the online version of (see data supplement to the online version of this paper) suggests that a number of this paper) suggests that a number of participants used the drug intermittently. participants used the drug intermittently.
Our longitudinal abstinence rates are Our longitudinal abstinence rates are relatively high compared with the values of relatively high compared with the values of 16% and 18% found by Couvee 
respectively. It is unlikely that this is due to a shorter It is unlikely that this is due to a shorter follow-up period, because most relapses follow-up period, because most relapses ( (4 490%) occur within the first 9 months. 90%) occur within the first 9 months. Two feasible explanations can be suggested. Two feasible explanations can be suggested. First, there were differences in the First, there were differences in the populations studied, as Holton populations studied, as Holton et al et al (1992) (1992) included referred participants in a psychiatric included referred participants in a psychiatric setting, and Couvee setting, and Couvée et al et al (2002) included a (2002) included a subgroup of long-term benzodiazepine users subgroup of long-term benzodiazepine users with depression. The results of several studies with depression. The results of several studies suggest that people with depression experisuggest that people with depression experience greater difficulty in stopping benzoence greater difficulty in stopping benzodiazepine use (Lader, 1994) . Second, diazepine use (Lader, 1994) . Second, because of the prospective nature of our because of the prospective nature of our study, both general practitioners and parstudy, both general practitioners and participants were aware that they would be ticipants were aware that they would be followed-up, whereas the follow-up in the followed-up, whereas the follow-up in the other studies was retrospective. other studies was retrospective.
The self-reported abstinence rates durThe self-reported abstinence rates during the last month of follow-up (52% for ing the last month of follow-up (52% for tapering off plus CBT tapering off plus CBT v.
v. 63% for tapering 63% for tapering off alone) replicate the findings of Rickels off alone) replicate the findings of Rickels et al et al (1991) and Golombok (1991) and Golombok et al et al (1987 Golombok et al et al ( ), (1987 , who found self-reported cross-sectional who found self-reported cross-sectional success rates at follow-up of 58% and success rates at follow-up of 58% and 54% respectively. Owing to the inter-54% respectively. Owing to the intermittent usage of benzodiazepines during mittent usage of benzodiazepines during follow-up, cross-sectional success rates follow-up, cross-sectional success rates overestimate the longitudinal effects. The overestimate the longitudinal effects. The significance of self-reported cross-sectional significance of self-reported cross-sectional success rates is questionable, since we success rates is questionable, since we included a control, in contrast to Rickels included a control, in contrast to Rickels et et al al (1991) and Golombok (1991) and Golombok et al et al (1987 Golombok et al et al ( ), but (1987 , but found no significant differences in the found no significant differences in the self-reported success rate between active self-reported success rate between active treatment and the control group. treatment and the control group.
One study showed a longitudinal abstiOne study showed a longitudinal abstinence rate of 82% (Ashton, 1987) . This nence rate of 82% (Ashton, 1987) . This study differed from the others in that it study differed from the others in that it was an evaluation of a patient-tailored was an evaluation of a patient-tailored withdrawal programme with tapering off withdrawal programme with tapering off periods of up to 15 months at a tertiary periods of up to 15 months at a tertiary clinical pharmacology unit that offered clinical pharmacology unit that offered pharmacological as well as psychological pharmacological as well as psychological support during tapering off. It is impossible support during tapering off. It is impossible to provide such highly specialised care in a to provide such highly specialised care in a primary care setting. primary care setting.
In line with the findings of the primary In line with the findings of the primary care study by Couvee care study by Couvée et al et al (2002) , the par-(2002), the participants in our study were not prescribed ticipants in our study were not prescribed more antidepressants or other psychotropic more antidepressants or other psychotropic drugs. This is in contrast to the results of drugs. This is in contrast to the results of Rickels Rickels et al et al (1991) , who found an increase (1991), who found an increase in the use of antidepressants by individuals in the use of antidepressants by individuals in psychiatric care who were taking part in in psychiatric care who were taking part in their tapering-off programme. their tapering-off programme.
We did not find that the addition of We did not find that the addition of psychotherapy to a tapering-off programme psychotherapy to a tapering-off programme was efficacious among benzodiazepine was efficacious among benzodiazepine users in the general population. Most users in the general population. Most previously published benzodiazepine dispreviously published benzodiazepine discontinuation studies that have assessed the continuation studies that have assessed the efficacy of additional psychotherapy were efficacy of additional psychotherapy were uncontrolled and evaluated a maximum of uncontrolled and evaluated a maximum of 21 patients per treatment arm (Oude 21 patients per treatment arm (Oude Voshaar Voshaar et al et al, 2006) . However, well-, 2006). However, welldesigned RCTs on the efficacy of additional designed RCTs on the efficacy of additional psychotherapy showed significantly superpsychotherapy showed significantly superior short-term effects in some specific ior short-term effects in some specific patient groups, namely those with panic patient groups, namely those with panic disorder (Otto disorder (Otto et al et al, 1993) 
